Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barasertib vs LDAC in elderly AML
NCT00952588Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of barasertib in acute myeloid leukemia (AML) (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall Complete Response Rate at 24 months. Started Jul 2009; status: completed.
02
Drugs
barasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00952588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952588.